TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Area of Science:

• Immunology
• Nephrology
• Molecular Biology

Background:

• Kidney disease is a growing global health issue, linked to aging, diabetes, hypertension, and immune disorders.
• Chronic kidney disease independently increases cardiovascular disease risk, exacerbating morbidity and mortality.
• Members of the tumor necrosis factor (TNF) superfamily are increasingly recognized for their roles in renal pathophysiology.

Purpose of the Study:

• To review the actions of TNF-related apoptosis-inducing ligand (TRAIL), osteoprotegerin (OPG), and TNF-like weaker inducer of apoptosis (TWEAK) in diabetic and non-diabetic kidney disease.
• To explore the clinical potential of these TNF superfamily members as biomarkers and therapeutic targets for kidney disease.

Main Methods:

• Literature review focusing on the involvement of TRAIL, OPG, and TWEAK in renal pathophysiology.
• Analysis of their roles in activating key pathways (e.g., NF-kappa B) and regulating cellular processes (proliferation, apoptosis, inflammation, fibrosis).
• Examination of their effects in both diabetic and non-diabetic kidney disease contexts.

Main Results:

• TRAIL, OPG, and TWEAK activate critical pathways implicated in kidney disease development and progression.
• These molecules regulate diverse cellular functions including proliferation, apoptosis, inflammation, angiogenesis, and fibrosis.
• Their effects exhibit a dual nature, varying with the specific type and stage of kidney injury.

Conclusions:

• TRAIL, OPG, and TWEAK play significant, albeit complex, roles in the pathogenesis of various kidney diseases.
• Further research into these TNF superfamily members could lead to novel diagnostic biomarkers and targeted therapies for kidney disease.
• Understanding their context-dependent actions is crucial for harnessing their clinical potential.